Rapid Novor: Funding, Investors & Team (Sep 2026)
Rapid Novor Inc., is the world's leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence antibody proteins without needing access to the producing cell line. As a University of Waterloo spin-off, the company continues to build its technology portfolios based on over twenty years of scientific research and inventions. The company’s mission is to advance life science for better human health with next-generation protein sequencing. Rapid Novor is a graduate from the Waterloo Accelerator Centre, is currently a member of Communitech and a resident company at JLABS @ Toronto.
Rapid Novor has raised $5.0M across 1 funding round on record, the most recent an undisclosed round of $5.0M announced in Jul 2020.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Rapid Novor Company Profile and Key Stats
Latest funding round on record: Jul 2020.
Rapid Novor Funding Rounds
Rapid Novor Founders and Leadership Team
Contact details for the Rapid Novor team: 1 of 1 has an email address on file.
Start 14-day free trial →Rapid Novor Funding Compared to Other Biotechnology Startups
Rapid Novor's latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Rapid Novor in Biotechnology and Kitchener
Companies Similar to Rapid Novor
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Rapid Novor Funding FAQs
What does Rapid Novor do?
Rapid Novor Inc., is the world's leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence antibody proteins without needing access to the producing cell line. As a University of Waterloo spin-off, the company continues to build its technology portfolios based on over twenty years of scientific research and inventions. The company’s mission is to advance life science for better human health with next-generation protein sequencing. Rapid Novor is a graduate from the Waterloo Accelerator Centre, is currently a member of Communitech and a resident company at JLABS @ Toronto.
How much funding has Rapid Novor raised?
Rapid Novor has raised $5.0M across 1 round on record. The most recent is an undisclosed round of $5.0M announced in Jul 2020.
When did Rapid Novor last raise funding?
Rapid Novor's most recent funding round on record is an undisclosed round of $5.0M, announced in Jul 2020.
Who is the CEO of Rapid Novor?
Mingjie Xie is listed as CEO at Rapid Novor.
Where is Rapid Novor headquartered?
Rapid Novor is based in Kitchener, Ontario, Canada.
How many employees does Rapid Novor have?
Rapid Novor is in the 11-50 employee band.
How does Rapid Novor's funding compare to other Biotechnology startups?
Rapid Novor's latest round of $5.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Rapid Novor Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Rapid Novor is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.